Published by Josh White on 14th March 2017
(ShareCast News) - CRISPR Therapeutics, a Nasdaq-listed biopharmaceutical company focussed on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer for developing CRISPR-based therapeutics in select disease areas, announced on Tuesday that they had signed a joint commercial license agreement with MaxCyte.